0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Significant advances in chemotherapy drugs have reduced mortality in patients with malignant tumors. However, chemotherapy-related cardiotoxicity increases the morbidity and mortality of patients, and has become the second leading cause of death after tumor recurrence, which has received more and more attention in recent years. Arrhythmia is one of the common types of chemotherapy-induced cardiotoxicity, and has become a new risk related to chemotherapy treatment, which seriously affects the therapeutic outcome in patients. Traditional Chinese medicine has experienced thousands of years of clinical practice in China, and has accumulated a wealth of medical theories and treatment formulas, which has unique advantages in the prevention and treatment of malignant diseases. Traditional Chinese medicine may reduce the arrhythmic toxicity caused by chemotherapy without affecting the anti-cancer effect. This paper mainly discussed the types and pathogenesis of secondary chemotherapeutic drug-induced arrhythmia (CDIA), and summarized the studies on Chinese medicine compounds, Chinese medicine Combination Formula and Chinese medicine injection that may be beneficial in intervention with secondary CDIA including atrial fibrillation, ventricular arrhythmia and sinus bradycardia, in order to provide reference for clinical prevention and treatment of chemotherapy-induced arrhythmias.

          Related collections

          Most cited references262

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Oxidative stress: a concept in redox biology and medicine

              Introduction The concept of oxidative stress has been introduced for research in redox biology and medicine in 1985, now 30 years ago, in an introductory chapter 1 in a book entitled ‘Oxidative Stress’ [2]. A concurrent comprehensive review entitled ‘Biochemistry of Oxidative Stress’ [3] presented the knowledge on pro-oxidants and antioxidants and their endogenous and exogenous sources and metabolic sinks. Since then, Redox Biology as a research area has found fulminant development in a wide range of disciplines, starting from chemistry and radiation biology through biochemistry and cell physiology all the way into general biology and medicine. A noteworthy insight, early on, was the perception that oxidation-reduction (redox) reactions in living cells are utilized in fundamental processes of redox regulation, collectively termed ‘redox signaling’ and ‘redox control’. A book ‘Antioxidant and Redox Regulation of Genes’ highlighted that development at an early stage [4]. Since then, an overwhelming and fascinating area of research has flourished, under the name of Redox Biology [5,6]. The concept of oxidative stress was updated to include the role of redox signaling [7], and there were efforts of redefining oxidative stress [8,9]. These developments were mirrored by the appearance of monographs, book series and the establishment of new research journals. Many volumes were published in Methods in Enzymology. An impressive number of new journals sprang up, Free Radical Research (initially Free Radical Research Communications), Free Radicals in Biology and Medicine, Redox Reports, Antioxidant Redox Signaling, and most recently Redox Biology. Useful as the term ‘oxidative stress’ may be in research, there has been an inflationary development in research circles and more so in the medical field and, even more than that, in public usage outside scientific endeavors (I would call it ‘over-stressing’ the term). This led to a dilution of the meaning, to overuse and even misuse. Cautionary words were published [10] and even explicit criticism was voiced [11,12]. “Over time, the mechanistic basis of the concept was largely forgotten and instead of the oxidative stress hypothesis becoming more precise in terms of molecular targets and mechanism, it became diffuse and nonspecific” [12]. In fact, an ‘oxidative stress hypothesis’ has not been formulated up to now. If anything, there were implicit deductions: for example, that because of the redox balance concept any single compound, e.g. a small-molecule redox-active vitamin, could alter the totality of the system. Such a view overlooks counterregulation and redundancies in the redox network. There is specificity inherent in the strategies of antioxidant defense [13]. Obviously, a general term describing a global condition cannot be meant to depict specific spatiotemporal chemical relationships in detail and in specific cells or organ conditions. Rather, it entails these, and directed effort is warranted to unravel the exact chemical and physical conditions and their significance in each case. Given the enormous variety and range of pro-oxidant and antioxidant enzymes and compounds, attempts were made to classify subforms of oxidative stress [7] and to conceptually introduce intensity scales ranging from physiological oxidative stress to excessive and toxic oxidative burden [14], as indicated in Table 1. There is ample evidence for the role of oxidation products of DNA, RNA, carbohydrates, proteins and lipids. What are the merits and pitfalls of ‘oxidative stress’ today? A comprehensive treatment of this question is to be deferred to an in-depth treatment (in preparation). However, for the purpose of the present Commentary it may suffice to collect a few thoughts: from its very nature, it is a challenge to combine the basic chemical notion of oxidation-reduction, including electron transfer, free radicals, oxygen metabolites (such as the superoxide anion radical, hydrogen peroxide, hydroxyl radical, electronically excited states such as singlet molecular oxygen, as well as the nitric oxide radical and peroxynitrite) with a biological concept, that of stress, first introduced by Selye in his research of adaptive responses [15,16]. The two words ‘oxidative’ and ‘stress’ elicit a notion which, in a nutshell, focuses on an important sector of fundamental processes in biology. This is a merit. Pitfalls are close-by: in research, simply to talk of ‘exposing cells or organisms to oxidative stress’ should clearly be discouraged. Instead, the exact molecular condition employed to change the redox balance of a given system is what is important; for example, in an experimental study cells were exposed to hydrogen peroxide, not to oxidative stress. Such considerations are even more appropriate in applications in the medical world. Quite often, redox components which are thought to be centrally important in disease processes are flatly denoted as oxidative stress; this can still be found in numerous schemes in the current biomedical literature. The underlying biochemically rigorous foundation may often be missing. Constructive criticism in this sense has been voiced repeatedly [11,12,17]. A related pitfall in this sense is the use of the term ROS, which stands for reactive oxygen species (the individual chemical reactants which were named in the preceding paragraph); whenever the specific chemical entity of the oxidant is known, that oxidant should be mentioned and discussed, not the generic ‘ROS’. This ‘one-size-fits-all’ mentality pervades also into the analytics: measuring so-called ‘total antioxidant capacity (TAC)’ in a blood plasma sample will not give useful information on the state of the organism, and should be discouraged [18]. Rather, individual antioxidant enzyme activities and patterns of antioxidant molecules need to be assessed. In view of the knowledge that the major burden of antioxidant defense is shouldered by antioxidant enzymes [13], it seems puzzling—in hindsight—that large human clinical studies based on one or two low-molecular-weight antioxidant compounds were undertaken. 3 What is attractive about ‘oxidative stress’? 3.1 Molecular redox switches What seems to be attractive about the term is the implicit notion of adaptation, coming from the general association of stress with stress response. This goes back to Selye's concept of stress as the ‘general adaptation syndrome’ [19]. The enormously productive field of molecular switches was opened by the discovery of phosphorylation/dephosphorylation, serving a mechanism in molecular signaling [20]. The role of redox switches came into focus more recently, foremost the dynamic role of cysteines in proteins, opening the field of the redox proteome, currently flourishing because of advances in mass spectrometric and imaging methodology [21–24]. A bridge between phosphorylation/dephosphorylation and protein cysteine reduction/oxidation is given by the redox sensitivity of critical cysteinyl residues in protein phosphatases, opening the molecular pathway for signaling cascades as fundamental processes throughout biology. What was particularly exciting to many researchers was the discovery of master switch systems [25], prominent examples being OxyR in bacteria [26] and NFkB [27] and Nrf2/Keap1 [28] in higher organisms. That batteries of enzyme activities are mustered by activation of gene transcription through a ‘simple’ redox signal is still an exciting strategy. Much of current effort in redox biology is addressed towards these response systems. Obviously, medical and pharmacological intervention attempts are a consequence. Outlook Current interest into the linkage of oxidative stress to inflammation and inflammatory responses is adding a new perspective. For example, inflammatory macrophages release glutathionylated peroxiredoxin-2, which then acts as a ‘danger signal’ to trigger the production of tumor necrosis factor-alpha [29]. The orchestrated responses to danger signals related to damage-associated molecular patterns (DAMPs) include relations to oxidative stress [30]. Under oxidative stress conditions, a protein targeting factor, Get3 in yeast (mammalian TRC40) functions as an ATP-independent chaperone [31]. More detailed molecular understanding will also deepen the translational impact into biology and medicine; as mentioned above, these aspects are beyond this Commentary and will be treated elsewhere. However, it might be mentioned, for example, that viral and bacterial infections are often associated with deficiencies in micronutrients, including the essential trace element, selenium, the redox-active moiety in selenoproteins. Selenium status may affect the function of cells in both adaptive and innate immunity [32]. Major diseases, now even diabetes Type 2, are being considered as ‘redox disease’ [33]. Molecular insight will enhance the thrust of the concept of oxidative stress, which is intimately linked to cellular energy balance. Thus, the subcellular compartmentation of redox processes and redox components is being studied at a new level, in mammalian cells [34] as well as in phototrophic organisms [35]. New insight from spatiotemporal organization of hydrogen peroxide metabolism [36] complements the longstanding interest in hydroperoxide metabolism in mammalian organs and its relationship to bioenergetics [37]. The following quote attributed to Hans Selye [38] might well apply to the concept of oxidative stress: “If only stress could be seen, isolated and measured, I am sure we could enormously lengthen the average human life span”.
                Bookmark

                Author and article information

                Contributors
                Role:
                URI : https://loop.frontiersin.org/people/2580182/overviewRole:
                URI : https://loop.frontiersin.org/people/1301553/overviewRole:
                Role:
                Role:
                Role:
                Role:
                Role:
                URI : https://loop.frontiersin.org/people/1527404/overviewRole: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/2342726/overviewRole: Role: Role: Role:
                Role: Role: Role: Role:
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                20 March 2024
                2024
                : 15
                : 1340855
                Affiliations
                [1] 1 Guang’anmen Hospital , China Academy of Chinese Medical Sciences , Beijing, China
                [2] 2 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion) , Tianjin, China
                [3] 3 Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) , Zhengzhou, Henan, China
                Author notes

                Edited by: Ruiwen Zhang, University of Houston, United States

                Reviewed by: Liang Guo, Bristol Myers Squibb, United States

                Olufunke Olorundare, University of Ilorin, Nigeria

                *Correspondence: Jie Li, qfm2020jieli@ 123456yeah.net ; Ling Feng, flgamyy@ 123456163.com ; Guifang Liu, lgf31@ 123456126.com
                [ † ]

                These authors have contributed equally to this work and share first authorship

                Article
                1340855
                10.3389/fphar.2024.1340855
                10987752
                38572424
                5653881a-469d-483e-ae0b-3e69913b01f9
                Copyright © 2024 Li, Cheng, Zhu, Hu, Wang, Niu, Li, Aierken, Li, Feng and Liu.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 19 November 2023
                : 05 March 2024
                Funding
                The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The work was supported by the Healthcare Special Project (No. 2022YB73), the Science and Technology Innovation Project of the China Academy of Traditional Chinese Medicine (No. CI 2021A03001), and the National Key Research and Development Program (No. 2019YFC1708404).
                Categories
                Pharmacology
                Review
                Custom metadata
                Ethnopharmacology

                Pharmacology & Pharmaceutical medicine
                chemotherapeutic drugs,traditional chinese medicine,arrhythmia,adverse effects,review

                Comments

                Comment on this article